Christopher Jewell

Company: Cartesian Therapeutics

Job title: Chief Scientific Officer

Bio:

Dr Jewell is the company’s CSO. His expertise in bioengineering, immunology, and nanotechnology span two decades of experience, including as the MPower Professor and Minta Martin Professor at the University of Maryland, a Consultant with the Boston Consulting Group, and an advisor to dozens of drug makers. Dr Jewell’s Research has resulted in $25M in funding and 130 manuscripts and patients, including work in Nature, Nature Materials, PNAS and Nature Biotechnology. Chris completed his PhD in Chemical Engineering at the University of Wisconsin, and was a Ragon Postdoctoral Fellow at MIT and Harvard

Seminars:

Keynote Presentation: Clinical & Mechanistic Perspective on Bringing Cell Therapies to Autoimmune Disease 10:00 am

Introducing RNA engineering for cell therapy Demonstrating deep and durable responses in patients receiving Descartes-08 without lymphodepletion or inpatient administration Insight into mechanisms behind Cartesian Therapeutics’ lead asset, Descartes-08Read more

day: Conference Day Two P1

Panel Discussion: Re-Evaluating Lymphodepletion to Improve Patient Access & Limit Therapeutic Side Effects 9:00 am

Consider the need for lymphodepletion on cell therapy to identify opportunities to remove preconditioning from therapies Identify characteristics of therapies that avoid lymphodepletion to pinpoint opportunities to broaden their benefits to more therapies Examine the impact of lymphodepletion on patient recruitment and accessibilityRead more

day: Conference Day Two P1